生物材料公司Nexgel宣布与新型战略合作伙伴Sequence Lifescience™达成关键合作。该合作伙伴主导了一轮总额550万美元的融资项目，旨在完成对Celularity Inc.退行性疾病治疗业务部门的收购交易。
此次战略性融资将显著加速Nexgel在细胞疗法领域的业务拓展，通过整合Celularity在退行性疾病领域的专利技术平台与临床资产，强化其在再生医学市场的竞争力。Sequence Lifescience™作为专注于生命科学领域投资的创新平台，此次牵头融资体现了市场对Nexgel技术路线与商业前景的认可。
交易完成后，Nexgel将获得Celularity在神经退行性疾病、骨关节疾病等领域的研发管线及相关知识产权，进一步丰富其产品组合。这项收购符合公司向高增长治疗领域战略转型的长期规划，预计将创造显著协同效应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.